Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2025 | Story Leonie Bolleurs | Photo Supplied
Dr Martin Clark
The Department of Geology at the UFS is co-hosting this year’s GeoCongress 2025 with the Geological Society of South Africa. Pictured is Dr Martin Clark, Senior Lecturer in the Department of Geology and convener of the congress.

The Department of Geology in the Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS) and the Geological Society of South Africa will co-host GeoCongress 2025, set to take place from 23 to 27 June 2025 on the UFS Bloemfontein Campus. This prestigious biennial academic event, themed: Embracing change through collaboration, will bring together leading academics, students, and industry experts from across South Africa to explore the latest advancements in geosciences.

The congress reflects the university's commitment to academic excellence, quality, and impact – core tenets of its UFS Vision 130. As a research-led, student-centred, and regionally engaged university, the UFS continues to transform itself to stay relevant within the dynamic and ever-changing international higher education sphere.

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation, says “The university is proud to co-host this major gathering of established and emerging earth scientists from a variety of disciplines, who will present relevant, timely research topics to a wider audience. The theme underscores the centrality of geosciences to our aspirations as a university for the country and continent, directing us towards a collective sustainable future. We are excited by the ideas to be featured at this conference. More importantly, we are inspired by the prospect of further promoting real interaction and innovation between academia, industry, and society for impactful change.”

A platform for scientific excellence

It is fitting for the UFS to co-host this event, as geologists in the Department of Geology as well as in the province have made significant contributions across multiple fields, including economic geology, palaeontology, and geomorphology.

In the Department of Geology, for instance, researchers are exploring a wide range of topics, including magmatic processes in the platinum-group-bearing Bushveld Igneous Complex, AI-driven prospectivity modelling of global deposits, meteorite impact-related processes in the Vredefort impact structure, and geological and structural studies in the Namaqualand region.

In the Free State, known for its rich mineral resources, including gold, diamonds, and coal, geologists have played a big role in exploring and developing these resources, particularly in the Free State Goldfields, one of South Africa’s leading gold-producing areas. The province also boasts significant coal deposits, important for power generation. In palaeontology, geologists have helped uncover valuable fossil sites, including the Florisbad hominid site, offering insights into the history of life on earth. Additionally, their research in geomorphology, especially around the Florisbad area, has shed light on unique landscapes and depositional environments, including lunette dunes.

In agriculture, geologists have worked closely with farmers to ensure sustainable land use, providing important information on soil composition and erosion prevention. They have also played a key role in the study of groundwater resources, helping to identify and assess borehole sites for irrigation and domestic water supply, which is key to farming in the region. The Institute for Groundwater Studies (IGS) at the UFS is the only institute in South Africa dedicated to geohydrology. Founded in 1974 by Prof FDI Hodgson, the IGS is the oldest institute at the university and has produced more than 1 000 postgraduate students. The institute conducts research on a wide variety of water-related topics. Of special interest is its contribution to the mining and industrial sectors in terms of water management, minimisation of pollution, as well as understanding the nature and behaviour of South Africa's aquifers. The IGS provides a complete service to these industries through field investigations, the development of specialised field equipment, an accredited laboratory, and computer models for aquifer management.

Building on these contributions in the field, GeoCongress 2025 marks an important event on South Africa’s geoscience calendar, showcasing the latest scientific advancements, innovative research, and practical applications shaping the industry. With engaging academic sessions, dynamic workshops, and practical field excursions, the conference offers attendees the opportunity to participate in meaningful discussions, attend insightful presentations, and take part in excursions that bring theory to life.

Opportunities for networking and growth

GeoCongress 2025 is more than just an academic gathering – it is an opportunity for professional growth and networking. Participants will meet peers, mentors, and industry leaders, establishing connections that can lead to new research projects and collaborations.

There is plenty to look forward to at this year's conference. Here are the key dates and event highlights for GeoCongress 2025. 

• Call for abstracts: Closes on 31 March 2025
• Early bird registration: Closes on 31 March 2025
• Final registration deadline: Closes on 22 June 2025

Event highlights:
• 23 and 24 June 2025: Pre-conference workshops and field trips
• 25 to 27 June 2025: Conference programme featuring keynote speakers, academic sessions, and networking opportunities

Registration fees:
• Standard registration: R3 500 (from 1 February 2025)
• Students and retirees: Flat rate of R500 (proof of registration required for students)

Additional costs:
• Workshops and one-day excursions: Visit the GeoCongress website for information on the costs

• Conference/gala dinner: R500

For more information, please contact us at secretariat@geocongress2025.org.za

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept